ArticleNPJ vaccines2019
A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease.
Article in NPJ vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 58 citations in OpenAlex.
- Vaccines against chronicExpert review of vaccines · 2026Review
- Immunization with the Tc85-Derived Peptide Displayed on Virus-like Particles Confers Protection againstACS omega · 2026Article
- Glycocalyx-Driven Immunomodulation in Trypanosoma cruzi: Structures, Host Responses, Diagnostic and Therapeutic Targeting.Parasite immunology · 2026Review
- Arming Inactivated Enveloped Virus Vaccines with theVaccines · 2026Review
- Conjugates of α-d-Galp-(1→3)-β-d-Galp for the serological diagnosis of Chagas disease.PLoS neglected tropical diseases · 2026Article
- Conjugation of Saccharidic Synthetic Antigens with Carrier Proteins by the Squaric Acid Method: Application as Biomarkers for Treatment Evaluation in Chagas Disease.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Is Zebrafish a Good Model for the Alpha-Gal Syndrome?FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
- The time has come for a vaccine against Chagas disease.Lancet regional health. Americas · 2025Review
- Tick salivary proteins metalloprotease and allergen-like p23 are associated with response to glycan α-Gal and mycobacterium infection.Scientific reports · 2025Article
- An Update on Vaccines AgainstPathogens (Basel, Switzerland) · 2025Review
- Review
- Article
- Exploring Peripheral Blood-Derived Extracellular Vesicles as Biomarkers: Implications for Chronic Chagas Disease with Viral Infection or Transplantation.Microorganisms · 2024Article
- Vaccination with parasite-specific TcTASV proteins combined with recombinant baculovirus as a delivery platform protects against acute and chronicFrontiers in cellular and infection microbiology · 2024Article
- Influence of microbiota-driven natural antibodies on dengue transmission.Frontiers in immunology · 2024Article
- An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study.PLoS neglected tropical diseases · 2024Article
- Mechanistic insights into the interaction between the host gut microbiome and malaria.PLoS pathogens · 2023Review
- Article
- Poly-L-Lysine-Based αGal-Glycoconjugates for Treating Anti-αGal IgE-Mediated Diseases.Frontiers in immunology · 2022Article
- Association of dengue infection with anti-alpha-gal antibodies, IgM, IgG, IgG1, and IgG2.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Chagas disease (ChD), caused by the hemoflagellate parasite
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.